Glioblastoma (GBM) is the most frequent primary tumor of the brain in adults. The median survival of GBM patients is 14.6 mo, 1 despite aggressive multimodal therapy. Thus, there is an urgent need for novel therapies for the treatment of GBM. One promising approach in this sense is represented by approaches that target functionally validated tumor-associated antigens (TAAs). Chondroitin sulfate proteoglycan 4 (CSPG4, best known as NG2) is involved in several processes that favor GBM progression and high NG2 expression levels have been shown to negatively impact disease outcome. [2] [3] [4] [5] As a proteoglycan on the cells surface, NG2 is amenable to antibody-based immunotherapy.
Although the immunoprivileged status of the nascent brain has been contested, there is a general consensus that GBM establishes multiple, coordinated mechanisms of escape from immunosurveillance, 6 both de novo and as result of treatment. GBM cells express high levels of MHC class I molecules, that are ligands for inhibitory killer immunoglobulin-like receptors (KIRs), thus inhibiting the antineoplastic activity of natural killer (NK) cells. In the GBM microenvironment, the cytokine balance is skewed toward the elicitation of antiinflammatory T H 2 responses and cancer cells mainly recruit immune cells with immunosuppressive properties. Although NK cells are not abundant within GBM lesions, representing 2.11 ± 0.54% of all lymphocytes, they exhibit the unusual CD56 dim CD16 -phenotype 6 . Moreover, GBM-infiltrating NK cells generally expressed activating killer cell lectin-like receptor subfamily K, member 1 (KLRK1, best known as NKG2D) receptors, which recognize stress ligands expressed by malignant cells. 6 Pellegata and colleagues observed an increase in circulating, interferon γ (IFNγ)-producing NK cells that was associated with improved survival in GBM patients subjected to dendritic cell-based vaccination. 7 Thus, anticancer treatments may activate endogenous NK cells against GBM. Taken together, these findings suggest that adoptively transferred, allogeneic NK cells may constitute a therapeutic option for GBM patients. Nevertheless, the therapeutic potential of purified NK cells against solid tumors has not been fully explored yet.
We have recently demonstrated that combining activated NK cells with a monoclonal antibody targeting NG2 (mAb9.2.27) inhibits tumor growth and prolongs the survival of GBMbearing rats. 8 The administration of NK cells plus mAb9.2.27 resulted in the recruitment to neoplastic lesions of pro-inflammatory ED1 + CCR2 low macrophages via the choroid plexus and blood vessels (Fig. 1) low cells exhibiting robust pro-inflammatory activity. This process may be regulated by miR-124, which has previously been shown to regulate the activation of microglial cells and macrophages in the central nervous system. 9 It is therefore conceivable that the pro-inflammatory environment established by NK cells plus mAb9.2.27 modulates miR-124, promoting the activation of macrophages and microglial cells as well as their maintenance in a classically activated phenotype.
Our findings support the notion that the immunomodulation properties of NK cells, and notably (1) their ability to secrete pro-inflammatory cytokines, and (2) generate immunosuppressive regulatory T cells (Tregs), which would limit the therapeutic efficacy of such an approach.
The use of mAb9.2.27 as a standalone therapeutic intervention induced temporary tumor regressions, presumably due to the immunoediting of NG2-expressing cells. Thus, simultaneously using monoclonal antibodies that are specific for several TAAs might reduce the selection of antigen loss tumor variants. Nevertheless, combining mAb9.2.27 with NK cells converted the tumor-promoting, anti-inflammatory microenvironment into a setting that allowed for therapeutically relevant tumor-specific immune responses. The selection of donors with NK cells expressing particular activating KIRs cognate to the MHCligands expressed by the patient GBM cells might further enhance the therapeutic potency of NK cells against GBM. However since NK cells may induce thrombocytopenia, and activated microglia are implicated in several neurological diseases, the safety, tolerable doses and duration of such a therapeutic approach requires stringent evaluations. Although it is desirable to study heterogeneous, patient-derived GBMs that pose significant therapeutic challenges, the role of Tregs might have been largely underestimated in studies relying on immunocompromised models. As NG2 is expressed on both malignant and angiogenic pericytes, humanized and/ or bispecific monoclonal antibodies that recognize NG2 epitopes on both these cell compartments may induce antibodydependent cell-mediated cytotoxicity (and hence mediate tumor destruction) more efficiently than molecules targeting either compartment alone. Furthermore, mAb9.2.27 may render cancer cells more susceptible to adjuvant chemoand radiotherapy, as we have previously demonstrated that NG2 signaling augments chemo and radioresistance in GBM cells. 4, 5 Moreover, the therapeutic potential of NK cells might be further enhanced by the co-administration of multiple agents, such as the proteasome inhibitor bortezomib, which not only sensitized GBM cells to death receptordependent apoptosis, but also stimulates the expression of stress-induced ligands. Additional NK cell-stimulatory agents include ligands for activatory receptors, anti-KIR antibodies, Toll-like receptor ligands and CpG oligodeoxynucleotides. 10 In summary, NK cells plus mAb9.2.27 converted the anti-inflammatory GBM microenvironment into a proinflammatory one dominated by M1-like macrophages and microglial cells that mediated tumor rejection. Our findings demonstrate the potential of targeting the tumor microenvironment as a means to stimulate endogenous immune responses and exert therapeutic effects against GBM.
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